Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Short Interest Update

Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Get Free Report) was the recipient of a large increase in short interest during the month of March. As of March 31st, there was short interest totalling 2,050,000 shares, an increase of 12.0% from the March 15th total of 1,830,000 shares. Approximately 3.6% of the company's shares are sold short. Based on an average trading volume of 585,700 shares, the days-to-cover ratio is presently 3.5 days.

Analysts Set New Price Targets

Several research analysts recently commented on the company. StockNews.com raised Aldeyra Therapeutics from a "sell" rating to a "hold" rating in a research note on Monday, January 29th. Oppenheimer upgraded shares of Aldeyra Therapeutics from a "market perform" rating to an "outperform" rating and set a $10.00 target price on the stock in a research note on Wednesday, April 3rd. Finally, HC Wainwright reiterated a "buy" rating and issued a $10.00 price target on shares of Aldeyra Therapeutics in a research note on Tuesday, April 2nd.

Insider Transactions at Aldeyra Therapeutics

In other news, CEO Todd C. Brady sold 97,914 shares of the firm's stock in a transaction on Monday, March 11th. The stock was sold at an average price of $3.27, for a total transaction of $320,178.78. Following the completion of the transaction, the chief executive officer now directly owns 1,556,622 shares in the company, valued at $5,090,153.94. The transaction was disclosed in a document filed with the SEC, which is available at this link. In related news, insider Bruce Greenberg sold 13,201 shares of the company's stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $3.41, for a total transaction of $45,015.41. Following the sale, the insider now directly owns 120,699 shares of the company's stock, valued at approximately $411,583.59. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Todd C. Brady sold 97,914 shares of the firm's stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $3.27, for a total transaction of $320,178.78. Following the completion of the transaction, the chief executive officer now directly owns 1,556,622 shares of the company's stock, valued at approximately $5,090,153.94. The disclosure for this sale can be found here. In the last three months, insiders have purchased 355,933 shares of company stock worth $1,473,245. 7.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Aldeyra Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Ameritas Investment Partners Inc. acquired a new stake in shares of Aldeyra Therapeutics in the second quarter valued at approximately $32,000. Prime Capital Investment Advisors LLC acquired a new stake in Aldeyra Therapeutics during the 4th quarter worth $35,000. Tower Research Capital LLC TRC grew its position in Aldeyra Therapeutics by 47,866.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,317 shares of the biotechnology company's stock worth $36,000 after purchasing an additional 4,308 shares during the last quarter. SG Americas Securities LLC acquired a new position in Aldeyra Therapeutics in the fourth quarter valued at $39,000. Finally, NorthRock Partners LLC purchased a new stake in shares of Aldeyra Therapeutics in the fourth quarter valued at about $42,000. 59.71% of the stock is currently owned by institutional investors and hedge funds.

Aldeyra Therapeutics Stock Performance

Shares of NASDAQ:ALDX traded down $0.15 on Friday, hitting $4.25. 582,033 shares of the company's stock were exchanged, compared to its average volume of 750,634. Aldeyra Therapeutics has a 1-year low of $1.42 and a 1-year high of $11.97. The company has a market capitalization of $250.31 million, a PE ratio of -6.64 and a beta of 1.51. The firm's 50-day moving average is $3.51 and its 200 day moving average is $3.31.

Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) last announced its quarterly earnings results on Thursday, March 7th. The biotechnology company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.13. On average, analysts anticipate that Aldeyra Therapeutics will post -0.14 EPS for the current fiscal year.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.